Mei-Ping Kung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mei-Ping Kung has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Hank F. Kung
Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
10 shared publicationsZhi-Ping Zhuang
Department of Radiology, University of Pennsylvania, 3700 Market Street, Room 305 Philadelphia, PA 19104, USA
9 shared publicationsCatherine Hou
Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
8 shared publicationsDaniel Skovronsky
Avid Radiopharmaceuticals Inc, Philadelphia, PA 19104, USA
4 shared publicationsBin Zhang
University of Pennsylvania School of Medicine
3 shared publicationsDaniel M. Skovronsky
University of Pennsylvania School of Medicine
2 shared publications
Latest Publications
- 31 May 2009
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 36 (4) , 411-417
Validation of an 18F-labeled biphenylalkyne as a positron emission tomography imaging agent for β-amyloid plaques
- 31 May 2009
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 36 (4) , 411-417
Validation of an 18F-labeled biphenylalkyne as a positron emission tomography imaging agent for β-amyloid plaques
- 28 February 2006
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 33 (2) , 203-209
Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker
- 28 February 2006
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 33 (2) , 203-209
Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker
- 1 December 2004
- Published by Elsevier in Brain Research
- Vol. 1031 (2) , 302
Erratum to “Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease” [Brain Research 1025 (2004) 98–105]
- 1 December 2004
- Published by Elsevier in Brain Research
- Vol. 1031 (2) , 302
Erratum to “Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease” [Brain Research 1025 (2004) 98–105]
- 1 October 2004
- Published by Elsevier in Brain Research
- Vol. 1025 (1-2) , 98-105
Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease
- 1 October 2004
- Published by Elsevier in Brain Research
- Vol. 1025 (1-2) , 98-105
Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease
- 9 March 2004
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 31 (8) , 1136-1145
Characterization of IMPY as a potential imaging agent for ?-amyloid plaques in double transgenic PSAPP mice
Deposition of β-amyloid (Aβ) plaques in the brain is likely linked to the pathogenesis of Alzheimer’s disease (AD). Developing specific Aβ aggregate-binding ligands as in vivo imaging agents may be useful for diagnosis and monitoring the progression of AD. We have prepared a thioflavin derivative, 6-iodo-2-(4’-dimethylamino-)phenyl-imidazo[1,2-a]pyridine, IMPY, which is readily radiolabeled with 125I/123I for binding or single-photon emission computerized tomography (SPECT) imaging studies. Characterization of [125I]IMPY binding to plaque-like structures was evaluated in double transgenic PSAPP mice. [125I]IMPY labeled Aβ plaques in transgenic mouse brain sections, and the labeling was consistent with fluorescent staining and Aβ-specific antibody labeling. Significant amounts of Aβ plaques present in the cortical, hippocampal, and entorhinal regions of the transgenic mouse brain were clearly detected with [125I]IMPY via ex vivo autoradiography. In contrast, [125I]IMPY showed little labeling in the age-matched control mouse brain. Tissue homogenate binding further corroborated the Aβ plaque-specific distribution in various brain regions of transgenic mouse, and correlated well with the known density of Aβ deposition. Using a tissue dissection technique, [125I]IMPY showed a moderate increase in the cortical region of transgenic mice as compared to the age-matched controls. In vitro blocking of [125I]IMPY by “carrier” observed via autoradiography in mouse brain sections was not replicated by an in vivo blocking experiment in living TT mouse brain. The failure was most likely due to a significant carrier effect, which slows down the tracer in vivo metabolism, leading to an increased brain uptake. Taken together, these data indicate that [123I]IMPY is a potentially useful SPECT imaging agent for in vivo labeling of Aβ plaques in the living brain.
- 9 March 2004
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 31 (8) , 1136-1145
Characterization of IMPY as a potential imaging agent for ?-amyloid plaques in double transgenic PSAPP mice
Deposition of β-amyloid (Aβ) plaques in the brain is likely linked to the pathogenesis of Alzheimer’s disease (AD). Developing specific Aβ aggregate-binding ligands as in vivo imaging agents may be useful for diagnosis and monitoring the progression of AD. We have prepared a thioflavin derivative, 6-iodo-2-(4’-dimethylamino-)phenyl-imidazo[1,2-a]pyridine, IMPY, which is readily radiolabeled with 125I/123I for binding or single-photon emission computerized tomography (SPECT) imaging studies. Characterization of [125I]IMPY binding to plaque-like structures was evaluated in double transgenic PSAPP mice. [125I]IMPY labeled Aβ plaques in transgenic mouse brain sections, and the labeling was consistent with fluorescent staining and Aβ-specific antibody labeling. Significant amounts of Aβ plaques present in the cortical, hippocampal, and entorhinal regions of the transgenic mouse brain were clearly detected with [125I]IMPY via ex vivo autoradiography. In contrast, [125I]IMPY showed little labeling in the age-matched control mouse brain. Tissue homogenate binding further corroborated the Aβ plaque-specific distribution in various brain regions of transgenic mouse, and correlated well with the known density of Aβ deposition. Using a tissue dissection technique, [125I]IMPY showed a moderate increase in the cortical region of transgenic mice as compared to the age-matched controls. In vitro blocking of [125I]IMPY by “carrier” observed via autoradiography in mouse brain sections was not replicated by an in vivo blocking experiment in living TT mouse brain. The failure was most likely due to a significant carrier effect, which slows down the tracer in vivo metabolism, leading to an increased brain uptake. Taken together, these data indicate that [123I]IMPY is a potentially useful SPECT imaging agent for in vivo labeling of Aβ plaques in the living brain.
- 1 January 2004
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 24 (1) , 049-054
Development and Evaluation of Iodinated Tracers Targeting Amyloid Plaques for SPECT Imaging
Successful development of iodinated ligands for various neurotransmitter receptors prompted us to explore the feasability of having iodinated ligands to target amyloid plaques of Alzheimer’s disease....
- 1 January 2004
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 24 (1) , 049-054
Development and Evaluation of Iodinated Tracers Targeting Amyloid Plaques for SPECT Imaging
Successful development of iodinated ligands for various neurotransmitter receptors prompted us to explore the feasability of having iodinated ligands to target amyloid plaques of Alzheimer’s disease....
- 1 January 2003
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 20 (1) , 15-24
Detection of Amyloid Plaques by Radioligands for Aβ40 and Aβ42: Potential Imaging Agents in Alzheimer's Patients
Alzheimer’s disease (AD) is linked to increased brain deposition of amyloid-β (Aβ) peptides in senile plaques (SPs), and recent therapeutic efforts have focused on inhibiting the production or...
- 1 January 2003
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 20 (1) , 15-24
Detection of Amyloid Plaques by Radioligands for Aβ40 and Aβ42: Potential Imaging Agents in Alzheimer's Patients
Alzheimer’s disease (AD) is linked to increased brain deposition of amyloid-β (Aβ) peptides in senile plaques (SPs), and recent therapeutic efforts have focused on inhibiting the production or...
- 1 January 2003
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 20 (3) , 249-254
Characterization of Radioiodinated Ligand Binding to Amyloid β Plaques
- 1 January 2003
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 20 (3) , 249-254
Characterization of Radioiodinated Ligand Binding to Amyloid β Plaques
- 1 November 2002
- Published by Elsevier in Brain Research
- Vol. 956 (2) , 202-210
IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques
- 1 November 2002
- Published by Elsevier in Brain Research
- Vol. 956 (2) , 202-210
IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques
- 1 August 2002
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 19 (1-2) , 7-10
Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in alzheimer’s disease
Development of probes for β-amyloid (Aβ) plaques, a critical factor associated with Alzheimer’s disease (AD), provides important tools for studying their role in AD. Previously, we reported [125I]IMSB and [125I]ISB as excellent probes for Aβ plaque labeling. Despite their exquisite in vitro binding characteristics, low brain uptakes (likely due to two ionizable carboxylic acid groups) limited their potential as in vivo imaging agents. To improve brain penetration, we have successfully prepared a neutral radioiodinated probe [125I]3. The improved probe displayed good binding affinity for Aβ aggregates (Ki=2.0 ± 0.2 using Aβ40 aggregates). In addition, the brominated counterpart displayed fluorescent-staining properties of Aβ plaques in postmortem AD brain sections similar to BSB, a fluoroscent probe reported previously. [125I]3 gave excellent plaque labeling by film autoradiography of AD brain sections. Unlike [125I]IMSB (which preferentially detects Aβ40 plaques), the improved radioioinated probe, [125I]3, can readily detect plaques containing aggregates of both Aβ40 and Aβ42. The initial brain uptake of [125I]3 in normal mice at 2 min p.i. was moderate (0.18% ID) and displayed a very slow washout from the brain (0.11 %.ID at 4 h p.i). Taken together, these data suggest that [125I]3 is useful for in vitro plaque detection, it may not be suitable for in vivo monitoring of Aβ progression and deposition.
- 1 August 2002
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 19 (1-2) , 7-10
Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in alzheimer’s disease
Development of probes for β-amyloid (Aβ) plaques, a critical factor associated with Alzheimer’s disease (AD), provides important tools for studying their role in AD. Previously, we reported [125I]IMSB and [125I]ISB as excellent probes for Aβ plaque labeling. Despite their exquisite in vitro binding characteristics, low brain uptakes (likely due to two ionizable carboxylic acid groups) limited their potential as in vivo imaging agents. To improve brain penetration, we have successfully prepared a neutral radioiodinated probe [125I]3. The improved probe displayed good binding affinity for Aβ aggregates (Ki=2.0 ± 0.2 using Aβ40 aggregates). In addition, the brominated counterpart displayed fluorescent-staining properties of Aβ plaques in postmortem AD brain sections similar to BSB, a fluoroscent probe reported previously. [125I]3 gave excellent plaque labeling by film autoradiography of AD brain sections. Unlike [125I]IMSB (which preferentially detects Aβ40 plaques), the improved radioioinated probe, [125I]3, can readily detect plaques containing aggregates of both Aβ40 and Aβ42. The initial brain uptake of [125I]3 in normal mice at 2 min p.i. was moderate (0.18% ID) and displayed a very slow washout from the brain (0.11 %.ID at 4 h p.i). Taken together, these data suggest that [125I]3 is useful for in vitro plaque detection, it may not be suitable for in vivo monitoring of Aβ progression and deposition.